Company intelligence / Profile preview
Tortugas Neuroscience
- Ownership
- Private
- Development stage
- Other
Overview
Tortugas Neuroscience is a preclinical-stage biotechnology company focused on developing novel small molecule therapeutics for central nervous system (CNS) disorders. The company's primary approach involves the activation of the potassium-chloride cotransporter 2 (KCC2), a protein essential for maintaining chloride homeostasis in neurons. By restoring KCC2 function, Tortugas aims to treat conditions characterized by neuronal over-excitation, such as epilepsy and neuropathic pain. The leadership team includes veterans from Sage Therapeutics, bringing significant expertise in neuroscience drug discovery. The company is backed by leading life science investors including ARCH Venture Partners and GV.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Tortugas Neuroscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tortugas Neuroscience.